Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 5/20 | 0.77 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18657494 | 0.89 | UBE2M (0.79) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657496 | 0.88 | UBE2M (0.81) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657517 | 0.87 | UBE2M (1.00) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL23077849 | 0.87 | UBE2M (0.59) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657839 | 0.80 | THRB (0.74) | UBE2MDCUN1D1GAAALDH1A1THRB | |
| SCHEMBL18657856 | 0.80 | UBE2M (0.69) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657842 | 0.80 | POLB (0.79) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657857 | 0.80 | UBE2M (0.68) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL18657848 | 0.79 | POLB (0.75) | UBE2MDCUN1D1POLBKMT2AMEN1 | |
| SCHEMBL23077847 | 0.74 | UBE2M (0.57) | UBE2MDCUN1D1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | UBE2M 8/4885DCUN1D1 3/4885POLB 1579/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | UBE2M 8/4885DCUN1D1 3/4885POLB 1579/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | UBE2M 8/4885DCUN1D1 3/4885POLB 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.